APX 5278
Alternative Names: APTA-5278; APX-5278Latest Information Update: 28 Aug 2024
At a glance
- Originator AptaBio Therapeutics
- Class Small molecules; Vascular disorder therapies
- Mechanism of Action NADPH oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Atherosclerosis in South Korea
- 13 Feb 2017 Early research in Atherosclerosis in South Korea before February 2017 (AptaBio Therapeutics pipeline, February 2017)